Essential Utilities (NYSE:WTRG) Stock

Essential Utilities

Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024.

Essential Utilities Inc

Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Visteon to report an earnings per share (EPS) of $1.89.
Anticipation surrounds Visteon's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $2.47, leading to a 2.05% increase in the share price the following trading session.
Here's a look at Visteon's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.97</td>
<td>1.84</td>
<td>1.97</td>
<td>1.68</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>4.44</td>
<td>2.26</td>
<td>2.54</td>
<td>1.61</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442126_0.png" alt="eps graph" />
<h3>Performance of Visteon Shares</h3>
Shares of Visteon were trading at $73.63 as of April 22. Over the last 52-week period, shares are down 31.99%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Observations about Visteon</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Visteon.
The consensus rating for Visteon is Neutral, based on 9 analyst ratings. With an average one-year price target of $92.0, there's a potential 24.95% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of and LCI Industries, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for LCI Industries, with an average 1-year price target of $96.0, suggesting a potential 30.38% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for and LCI Industries, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visteon</td>
<td>Neutral</td>
<td>-5.15%</td>
<td>$134M</td>
<td>10.11%</td>
</tr>
<tr>
<td>LCI Industries</td>
<td>Neutral</td>
<td>-4.11%</td>
<td>$169.41M</td>
<td>0.68%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Visteon is positioned at the bottom for Revenue Growth and Gross Profit among its peers. However, it has a higher Return on Equity compared to its peers.
<h3>About Visteon</h3>
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The Company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America and Others.
<h3>Visteon: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Visteon faced challenges, resulting in a decline of approximately -5.15% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Visteon's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.11%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.24%, the company showcases effective utilization of assets.
Debt Management: Visteon's debt-to-equity ratio is below the industry average. With a ratio of 0.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/VC/earnings">To track all earnings releases for Visteon visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

What's Next: Visteon's Earnings Preview

Earnings Beats

Earnings Misses

News

INBK

First Internet Q1 EPS $0.11 May Not Compare To $0.76 Estimate, Sales $35.52M Beat $26.43M Estimate

ConnectOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNOB#NASDAQ">CNOB</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that ConnectOne Bancorp will report an earnings per share (EPS) of $0.46.
ConnectOne Bancorp bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.09, leading to a 1.08% increase in the share price the following trading session.
Here's a look at ConnectOne Bancorp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.43</td>
<td>0.44</td>
<td>0.41</td>
<td>0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.52</td>
<td>0.41</td>
<td>0.46</td>
<td>0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442102_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ConnectOne Bancorp were trading at $22.07 as of April 22. Over the last 52-week period, shares are up 21.07%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CNOB/earnings">To track all earnings releases for ConnectOne Bancorp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNOB

Exploring ConnectOne Bancorp's Earnings Expectations

Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBCP#NASDAQ">IBCP</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Independent Bank will report an earnings per share (EPS) of $0.70.
The announcement from Independent Bank is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.11, which was followed by a 1.02% increase in the share price the next day.
Here's a look at Independent Bank's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.76</td>
<td>0.76</td>
<td>0.70</td>
<td>0.64</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.87</td>
<td>0.81</td>
<td>0.88</td>
<td>0.76</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442071_0.png" alt="eps graph" />
<h3>Performance of Independent Bank Shares</h3>
Shares of Independent Bank were trading at $30.96 as of April 22. Over the last 52-week period, shares are up 24.27%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IBCP/earnings">To track all earnings releases for Independent Bank visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IBCP

Earnings Outlook For Independent Bank

SkyWest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate SkyWest to report an earnings per share (EPS) of $2.05.
The market awaits SkyWest's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.53, leading to a 3.56% increase in the share price on the subsequent day.
Here's a look at SkyWest's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.81</td>
<td>1.92</td>
<td>1.73</td>
<td>1.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.34</td>
<td>2.16</td>
<td>1.82</td>
<td>1.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>6.0%</td>
<td>-9.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442058_0.png" alt="eps graph" />
<h3>Tracking SkyWest's Stock Performance</h3>
Shares of SkyWest were trading at $85.63 as of April 22. Over the last 52-week period, shares are up 18.94%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on SkyWest</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on SkyWest.
Analysts have given SkyWest a total of 3 ratings, with the consensus rating being Outperform. The average one-year price target is $124.0, indicating a potential 44.81% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Joby Aviation, Alaska Air Gr and JetBlue Airways, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Joby Aviation, with an average 1-year price target of $8.0, suggesting a potential 90.66% downside.</li>
<li>Analysts currently favor an Buy trajectory for Alaska Air Gr, with an average 1-year price target of $69.43, suggesting a potential 18.92% downside.</li>
<li>Analysts currently favor an Neutral trajectory for JetBlue Airways, with an average 1-year price target of $4.44, suggesting a potential 94.81% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Joby Aviation, Alaska Air Gr and JetBlue Airways, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SkyWest</td>
<td>Outperform</td>
<td>25.62%</td>
<td>$218.77M</td>
<td>4.13%</td>
</tr>
<tr>
<td>Joby Aviation</td>
<td>Buy</td>
<td>-94.67%</td>
<td>$33K</td>
<td>-29.09%</td>
</tr>
<tr>
<td>Alaska Air Gr</td>
<td>Buy</td>
<td>38.43%</td>
<td>$531M</td>
<td>1.60%</td>
</tr>
<tr>
<td>JetBlue Airways</td>
<td>Neutral</td>
<td>-2.06%</td>
<td>$426M</td>
<td>-1.67%</td>
</tr>
</tbody>
</table>

Key Takeaway:
SkyWest ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity.
<h3>Delving into SkyWest's Background</h3>
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. Generally, SkyWest provides regional flights, and utilizes its smaller, lower-cost aircraft to carry passengers that booked tickets through airlines. It partners with carriers across the world to fly and operate aircraft for a fee. SkyWest may use the carriers's brand and ground support to coordinate marketing and easily transport passengers. The company has two reportable segments: SkyWest Airlines, which generates maximum revenue, and SkyWest Leasing.
<h3>SkyWest: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining SkyWest's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.62% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: SkyWest's net margin excels beyond industry benchmarks, reaching 10.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): SkyWest's ROE excels beyond industry benchmarks, reaching 4.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): SkyWest's ROA stands out, surpassing industry averages. With an impressive ROA of 1.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.15.
<a href="https://www.benzinga.com/quote/SKYW/earnings">To track all earnings releases for SkyWest visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SKYW

Exploring SkyWest's Earnings Expectations

In the last three months, 7 analysts have published ratings on BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $111.0, a high estimate of $124.00, and a low estimate of $100.00. A decline of 8.01% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745442055_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive BOK Financial. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jon Arfstrom &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $104.00&#x7C;$119.00 &#x7C; 
&#x7C;Peter Winter &#x7C;DA Davidson &#x7C;Lowers &#x7C;Buy &#x7C; $114.00&#x7C;$122.00 &#x7C; 
&#x7C;Matt Olney &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $110.00&#x7C;$124.00 &#x7C; 
&#x7C;Matt Olney &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $124.00&#x7C;$124.00 &#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $100.00&#x7C;$120.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $110.00&#x7C;$115.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Announces &#x7C;Equal-Weight &#x7C; $115.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BOK Financial. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of BOK Financial compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of BOK Financial's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into BOK Financial's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BOKF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BOK Financial analyst ratings.</a>
<h2>All You Need to Know About BOK Financial</h2>
BOK Financial Corp is a financial institution in Oklahoma, and it provides a comprehensive range of nationally competitive financial products and services. Its operating segments consist of commercial banking, consumer banking, and wealth management. The company has various products and services, including cash management services, loans and deposits, fiduciary and insurance services, mortgage banking, and brokerage and trading services. It generates maximum revenue from the commercial banking segment. Its commercial banking segment includes lending, treasury and cash management services, and customer risk management products to small businesses, middle market, and larger commercial customers.
<h3>Breaking Down BOK Financial's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: BOK Financial's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 14.31%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: BOK Financial's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 24.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.12%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): BOK Financial's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.24%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.57, BOK Financial faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BOKF

What Analysts Are Saying About BOK Financial Stock

Across the recent three months, 8 analysts have shared their insights on Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Travere Therapeutics, presenting an average target of $40.75, a high estimate of $47.00, and a low estimate of $31.00. This upward trend is apparent, with the current average reflecting a 18.12% increase from the previous average price target of $34.50.
<img src="https://www.benzinga.com/files/images/story/2025/1745442045_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Travere Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $47.00&#x7C;$47.00 &#x7C; 
&#x7C;Edward Nash &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $47.00&#x7C;$45.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $31.00&#x7C;$29.00 &#x7C; 
&#x7C;Anupam Rama &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $44.00&#x7C;$42.00 &#x7C; 
&#x7C;Carly Kenselaar &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $35.00&#x7C;$31.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $32.00&#x7C;$27.00 &#x7C; 
&#x7C;Liisa Bayko &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $45.00&#x7C;$33.00 &#x7C; 
&#x7C;Edward Nash &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $45.00&#x7C;$22.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Travere Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Travere Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Travere Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Travere Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TVTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Travere Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Travere Therapeutics Better</h2>
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
<h3>Travere Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Travere Therapeutics displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 65.98%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Travere Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -80.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -421.09%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.97%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Travere Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 6.8. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TVTX

Assessing Travere Therapeutics: Insights From 8 Financial Analysts

4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Becton Dickinson, revealing an average target of $270.0, a high estimate of $280.00, and a low estimate of $260.00. This current average represents a 2.88% decrease from the previous average price target of $278.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745442035_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Becton Dickinson by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $260.00&#x7C;$280.00 &#x7C; 
&#x7C;Travis Steed &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $261.00&#x7C;$279.00 &#x7C; 
&#x7C;Travis Steed &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $279.00&#x7C;$278.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $280.00&#x7C;$275.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Becton Dickinson. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Becton Dickinson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Becton Dickinson's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Becton Dickinson analyst ratings.</a>
<h2>About Becton Dickinson</h2>
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
<h3>Breaking Down Becton Dickinson's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Becton Dickinson's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 9.82%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Becton Dickinson's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 5.86%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Becton Dickinson's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.19%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Becton Dickinson's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.54%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.74.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Becton Dickinson

In the last three months, 16 analysts have published ratings on Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Texas Roadhouse, presenting an average target of $185.62, a high estimate of $213.00, and a low estimate of $164.00. This current average has decreased by 5.02% from the previous average price target of $195.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1745442027_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Texas Roadhouse is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jon Tower &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $164.00&#x7C;$213.00 &#x7C; 
&#x7C;Jeffrey Bernstein &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $179.00&#x7C;$178.00 &#x7C; 
&#x7C;Zachary Fadem &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $170.00&#x7C;$175.00 &#x7C; 
&#x7C;Chris O'Cull &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $170.00&#x7C;$172.00 &#x7C; 
&#x7C;David Tarantino &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $180.00&#x7C;$198.00 &#x7C; 
&#x7C;Nick Setyan &#x7C;Wedbush &#x7C;Raises &#x7C;Outperform &#x7C; $210.00&#x7C;$200.00 &#x7C; 
&#x7C;John Ivankoe &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $184.00&#x7C;$185.00 &#x7C; 
&#x7C;Gregory Francfort &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $200.00&#x7C;$205.00 &#x7C; 
&#x7C;Jim Salera &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $180.00&#x7C;$186.00 &#x7C; 
&#x7C;Logan Reich &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $180.00&#x7C;$200.00 &#x7C; 
&#x7C;Jon Tower &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $213.00&#x7C;$212.00 &#x7C; 
&#x7C;Jake Bartlett &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $205.00&#x7C;$209.00 &#x7C; 
&#x7C;Chris O'Cull &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $172.00&#x7C;$185.00 &#x7C; 
&#x7C;Nick Setyan &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $200.00&#x7C;$220.00 &#x7C; 
&#x7C;Jeffrey Bernstein &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $178.00&#x7C;$194.00 &#x7C; 
&#x7C;Chris O'Cull &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $185.00&#x7C;$195.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Texas Roadhouse. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Texas Roadhouse compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Texas Roadhouse's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Texas Roadhouse's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TXRH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Texas Roadhouse analyst ratings.</a>
<h2>Unveiling the Story Behind Texas Roadhouse</h2>
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches.
<h3>Financial Insights: Texas Roadhouse</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Texas Roadhouse displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 23.49%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Texas Roadhouse's net margin is impressive, surpassing industry averages. With a net margin of 8.06%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Texas Roadhouse's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 8.69%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Texas Roadhouse's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.79% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Texas Roadhouse's debt-to-equity ratio is below the industry average at 0.63, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TXRH

Forecasting The Future: 16 Analyst Projections For Texas Roadhouse

Providing a diverse range of perspectives from bullish to bearish, 27 analysts have published ratings on Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">10</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $35.63, with a high estimate of $42.00 and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 3.16% from the previous average price target of $34.54.
<img src="https://www.benzinga.com/files/images/story/2025/1745442020_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Confluent among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Howard Ma &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $38.00&#x7C;$38.00 &#x7C; 
&#x7C;Yun Kim &#x7C;Loop Capital &#x7C;Lowers &#x7C;Hold &#x7C; $22.00&#x7C;$30.00 &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $32.00&#x7C;$42.00 &#x7C; 
&#x7C;Raimo Lenschow &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $29.00&#x7C;$37.00 &#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $25.00&#x7C;$32.00 &#x7C; 
&#x7C;Mark Cash &#x7C;Raymond James &#x7C;Announces &#x7C;Outperform &#x7C; $30.00&#x7C;- &#x7C; 
&#x7C;Miller Jump &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $35.00&#x7C;$40.00 &#x7C; 
&#x7C;Patrick Walravens &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Yun Kim &#x7C;Loop Capital &#x7C;Lowers &#x7C;Hold &#x7C; $30.00&#x7C;$34.00 &#x7C; 
&#x7C;Patrick Walravens &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Mike Cikos &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Austin Dietz &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $38.00&#x7C;$34.00 &#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $32.00&#x7C;$30.00 &#x7C; 
&#x7C;Miller Jump &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $40.00&#x7C;$35.00 &#x7C; 
&#x7C;Karl Keirstead &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $34.00&#x7C;$26.00 &#x7C; 
&#x7C;Matthew Swanson &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $41.00&#x7C;$36.00 &#x7C; 
&#x7C;Nick Altmann &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $35.00&#x7C;$27.00 &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $42.00&#x7C;$40.00 &#x7C; 
&#x7C;Howard Ma &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $38.00&#x7C;$35.00 &#x7C; 
&#x7C;Brad Reback &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $40.00&#x7C;$37.00 &#x7C; 
&#x7C;Rob Owens &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $40.00&#x7C;$35.00 &#x7C; 
&#x7C;Chirag Ved &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $40.00&#x7C;$32.00 &#x7C; 
&#x7C;Kingsley Crane &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $38.00&#x7C;$34.00 &#x7C; 
&#x7C;Mike Cikos &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $40.00&#x7C;$31.00 &#x7C; 
&#x7C;Raimo Lenschow &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $37.00&#x7C;$35.00 &#x7C; 
&#x7C;Brad Sills &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $31.00&#x7C;$26.00 &#x7C; 
&#x7C;Howard Ma &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $35.00&#x7C;$32.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Confluent. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Confluent compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Confluent's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Confluent's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CFLT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Confluent analyst ratings.</a>
<h2>Discovering Confluent: A Closer Look</h2>
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
<h3>Key Indicators: Confluent's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Confluent displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 22.53%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Confluent's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -33.71%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Confluent's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -9.29%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Confluent's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.32%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Confluent's debt-to-equity ratio surpasses industry norms, standing at 1.15. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CFLT

27 Analysts Assess Confluent: What You Need To Know

In the current market session, James Hardie Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) price is at $23.60, after a 4.89% increase. However, over the past month, the stock decreased by 1.43%, and in the past year, by 32.73%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745442018_0.png" alt="Past Year Chart" />

<h3>A Look at James Hardie Industries P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
James Hardie Industries has a better P/E ratio of 22.28 than the aggregate P/E ratio of 16.53 of the Construction Materials industry. Ideally, one might believe that James Hardie Industries Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745442018_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for James Hardie Industries

In the latest quarter, 8 analysts provided ratings for Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Macerich and provided 12-month price targets. The average target is $17.8, accompanied by a high estimate of $21.00 and a low estimate of $14.40. This current average represents a 11.4% decrease from the previous average price target of $20.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1745442012_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Macerich among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $16.00&#x7C;$21.00 &#x7C; 
&#x7C;Ki Bin Kim &#x7C;Truist Securities &#x7C;Maintains &#x7C;Buy &#x7C; $19.00&#x7C;$19.00 &#x7C; 
&#x7C;Ronald Kamdem &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $19.00&#x7C;$20.00 &#x7C; 
&#x7C;Ki Bin Kim &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $19.00&#x7C;$23.00 &#x7C; 
&#x7C;Caitlin Burrows &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Sell &#x7C; $14.40&#x7C;$16.70 &#x7C; 
&#x7C;Michael Mueller &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $18.00&#x7C;$22.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $21.00&#x7C;$22.00 &#x7C; 
&#x7C;Alexander Goldfarb &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Underweight &#x7C; $16.00&#x7C;$17.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Macerich. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Macerich compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Macerich's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MAC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Macerich analyst ratings.</a>
<h2>Get to Know Macerich Better</h2>
Macerich invests in premium mall assets. The company owns 30 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.9 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in December 2024.
<h3>Financial Milestones: Macerich's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Macerich's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 14.66%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Macerich's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -77.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Macerich's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.03%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Macerich's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.62%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.84.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Macerich Stock

Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has outperformed the market over the past 5 years by 20.59% on an annualized basis producing an average annual return of 33.97%. Currently, Dell Technologies has a market capitalization of $62.60 billion. 
Buying $100 In DELL: If an investor had bought $100 of DELL stock 5 years ago, it would be worth $438.54 today based on a price of $89.70 for DELL at the time of writing.
<h3>Dell Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745442013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

DELL

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVX#NASDAQ">NAVX</a>) stock traded higher on Wednesday.
In an SEC filing, Novavax <a target="_blank" href="https://www.benzinga.com/secfilings/25/04/44946464/novavax-inc-general-corporate-statement-form8" rel="noreferrer noopener">said</a>, &#8220;We believe that our Biologics License Application (BLA) is approvable based on conversations with U.S. Food and Drug Administration (FDA), as of our Prescription Drug User Fee Act date on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">April 1 and through today</a>.&#8221;
The company said that it received formal communication from the FDA in the form of an information request for a post-marketing commitment to generate additional clinical data.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" rel="noreferrer noopener">Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst</a>
&#8220;We look forward to engaging with the FDA expeditiously to address the PMC request and move to approval as soon as possible,&#8221; the company <a target="_blank" href="https://www.benzinga.com/secfilings/25/04/44946464/novavax-inc-general-corporate-statement-form8" rel="noreferrer noopener">said</a> in the SEC filing on Wednesday.&nbsp;&nbsp;
According to a media report in early April, the regulators missed the deadline for deciding to grant full <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613147/fda-delays-full-approval-decision-on-novavaxs-covid-19-vaccine" rel="noreferrer noopener">approval to Novavax&#8217;s shot</a>.
The Wall Street Journal reports that the agency is now delaying the decision and has reportedly requested more data, making it unlikely that the application will be approved soon, according to sources.
In April, Novavax released preliminary results from the SHIELD-Utah&nbsp;study investigating the effects of systemic and local reactogenicity of COVID-19&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44824383/novavax-covid-vaccine-shows-milder-side-effects-than-pfizer-biontechs-shot-study" rel="noreferrer noopener">vaccine doses in&nbsp;Utah</a>.
SHIELD-Utah&nbsp;was a prospective, interventional study conducted at the&nbsp;University of Utah&nbsp;Health.
The study showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula), targeting the JN.1 strain, resulted in fewer and less severe reactogenicity symptoms when compared with the&nbsp;Pfizer Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)-BioNTech SE's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44808832/shield-utah-study-shows-novavaxs-covid-19-vaccine-induces-lower-reactogenicity-symptoms-compared-t" rel="noreferrer noopener">mRNA 2024-2025 vaccine</a>.
In September 2024, the U.S. Food And Drug Administration (FDA) granted Emergency Use Authorization to&nbsp;Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants" rel="noreferrer noopener">individuals aged 12 and older</a>.
Novavax&#8217;s vaccine was included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on&nbsp;June 27, 2024.
<h2 class="wp-block-heading">Novavax Stock Prediction For 2025</h2>
Equity research analysts, both on and off Wall Street, typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Novavax, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. 
For Novavax, the 200-day moving average sits at $9.94, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $7.33. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: NVAX stock was up 19.5% at $7.47 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs" target="_blank" rel="noreferrer noopener">Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Health Care

Movers

General

BNTX

NAVX

NVAX

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.44 by 2.27 percent. This is a 4.26 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $73.11 million which beat the analyst consensus estimate of $70.96 million by 3.02 percent. This is a 4.01 percent increase over sales of $70.28 million the same period last year.

OSBC

Old Second Bancorp Q1 Adj. EPS $0.45 Beats $0.44 Estimate, Sales $73.11M Beat $70.96M Estimate

Intuitive Surgical Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported first-quarter 2025 revenue of $2.25 billion, beating analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimates&nbsp;of $2.19 billion</a>.
Total revenue was up 19% year-over-year as Worldwide da Vinci procedures increased by approximately 17%. The company placed 367 da Vinci surgical systems in the quarter, compared to 313 in the same quarter of the prior year. Intuitive Surgical&#8217;s da Vinci surgical system installed base grew to 10,189 systems as of March 31, <a href="https://www.benzinga.com/pressreleases/25/04/g44936280/intuitive-announces-first-quarter-earnings" target="_blank" rel="noreferrer noopener">up 15% year-over-year</a>.
The company reported first-quarter adjusted earnings of $1.81 per share, beating analyst estimates of $1.72 per share.
Guidance: Intuitive Surgical expects the full-year 2025 worldwide da Vinci procedures to increase by approximately 15%-17%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44259507/goldman-sachs-gains-confidence-in-market-rebound-upgrades-ge-healthcare-amid-china-recovery-hopes" rel="noreferrer noopener">Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes</a>
The company expects a gross profit margin of 65% to 66.5% in 2025, which includes an estimated 1.7% impact from tariffs.
Truist Securities cut the price target from $605 to $590 on Tuesday, while maintaining a Buy rating, due to a lower 2026 estimated EPS, which reflects the incremental tariff impact — and likely leaves room for upside for the robotic-assisted surgery company.
Analyst Richard Newitter writes, &#8220;We think the stock deserves a premium multiple given elevated procedure growth and a new product cycle now in-hand which has potential to drive significant rev and EPS growth acceleration and upside vs. our/CNS thinking into the out-years. Although tariffs remain a NT headwind, it&#8217;s a manageable one in our view that we think investors will gradually begin to look through given ISRG is a leading innovator&#8230;&#8221;
William Blair analyst Brandon Vazquez wrote on Wednesday, &#8220;On macro dynamics, uncertainty around Medicaid, and subsequently capex budgets, will admittedly linger on the stock for the time being.&#8221;
William Blair notes that the management said U.S. capital spending hasn&#8217;t slowed down much yet, but international markets are starting to feel pressure as more money gets shifted toward defense.
Intuitive&#8217;s leasing model is helping hospitals manage tight budgets. Still, investors are keeping a close eye on the situation—especially with possible Medicaid cuts that could tighten hospital finances. While it&#8217;s hard to predict if those cuts will happen due to the current political climate, they could have a huge impact, as around 16% of U.S. adults rely on Medicaid.
Stifel analyst on Tuesday wrote, &#8220;Our procedure growth focus reminds us that system placements drive future procedures, top-line growth, and future margin expansion&#8230;and this 1Q25 procedure growth was an encouraging start to the year. While ISRG was pressured in after-hours trading, we expect investors will find a lot to like as they review further Intuitive&#8217;s 1Q25 results and key performance metrics.&#8221;
Analyst Rick Wise says the $9.1 billion cash position and zero debt offer excellent balance sheet flexibility and the opportunity to buy back shares. Stifel maintains a price target of $670 <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings" target="_blank" rel="noreferrer noopener">with a Buy rating</a>.
Price Action: ISRG stock is up 2.47% to $490.58 at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44955951/ge-vernova-can-mitigate-tariff-and-inflation-concerns-after-strong-q1-sticks-to-annual-outlook" target="_blank" rel="noreferrer noopener">GE Vernova Can Mitigate Tariff And Inflation Concerns After Strong Q1, Sticks To Annual Outlook</a></li>
</ul>

Analyst Color

Large Cap

Guidance

ISRG

Analysts Remain Bullish On Intuitive Surgical Despite Macro Uncertainty

Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/04/n44964122/las-vegas-sands-reports-first-quarter-2025-results">details from the report.&nbsp;</a>
The Details: Las Vegas Sands reported quarterly earnings of 59 cents per share, which beat the analyst consensus estimate of 58 cents. Quarterly revenue came in at $2.86 billion, which missed the analyst consensus estimate of $2.91 billion and is down from revenue of $2.96 billion year-over-year.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
&#8220;We continued to execute our strategic objectives during the quarter. We remain enthusiastic about our opportunities to deliver industry-leading growth in both Macao and Singapore in the years ahead as we execute our capital investment programs in both markets,&#8221; said Robert G. Goldstein, CEO of Las Vegas Sands. 
The CEO also highlighted Marina Bay Sands in Singapore as delivering &#8220;outstanding financial and operating performance.&#8221; 
LVS Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Las Vegas Sands stock was down 0.32% after hours at $34.54 Wednesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Gaming

After-Hours Center

Las Vegas Sands Stock Down Slightly After Mixed Q1 Results: EPS Beat, Revenue Misses

Core Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) is looking for Q2 GAAP EPS of $0.17-$0.21 vs $0.24 analyst estimate. sees sales of $128.000 million-$134.000 million vs $136.01 million analyst estimate.

Core Laboratories Sees Q2 GAAP EPS $0.17-$0.21 vs $0.24 Est; Sees Sales $128.000M-$134.000M vs $136.01M Est

Whitecap Res (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WCP#TSX">WCP</a>) reported quarterly earnings of $0.27 per share. This is a 170 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $942.20 million which beat the analyst consensus estimate of $734.00 million by 28.37 percent. This is a 8.51 percent increase over sales of $868.30 million the same period last year.

TSX:WCP

Whitecap Res Q1 EPS $0.27 Up From $0.10 YoY, Sales $942.20M Beat $734.00M Estimate

Core Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.19 by 26.32 percent. This is a 26.32 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $123.58 million which missed the analyst consensus estimate of $129.80 million by 4.79 percent. This is a 4.67 percent decrease over sales of $129.64 million the same period last year.

Core Laboratories Q1 Adj. EPS $0.14 Misses $0.19 Estimate, Sales $123.58M Miss $129.80M Estimate

Press Releases

Aqua Pennsylvania Acquires Greenville Sanitary Authority Wastewater System in Mercer County

Essential Utilities Declares June 2025 Dividend

Essential Utilities Reports Financial Results for Full Year 2024

Essential Utilities Announces Ed Vallejo as New Investor Relations Director

Aqua Pennsylvania Reminds Customers to Apply for 2025 Water and Wastewater Bill Assistance

Essential Utilities Marks Five Years of Strength, Innovation and Growth

Essential Utilities Reminds Customers and Contractors to Practice Safe Digging by Calling 811

Essential Utilities Strengthens America's Infrastructure Through $1B+ Capital Improvement Program

Essential Utilities to Report Earnings for Q1 2025

One Year After First Federal PFAS Guidelines, Aqua Pennsylvania on Track to Meet 2029 Compliance Deadline

WTRG

Artesian Resources Corporation - Class A Non-Voting Common Stock

Artesian Resources

American Water Works Company, Inc. Common Stock

American Water Works Co

American States Water Company Common Stock

American States Water

Cadiz

Consolidated Water Co. Ltd. - Ordinary Shares

Consolidated Water Co

California Water Service Group Common Stock

California Water Servs Gr

Global Water Resources, Inc. - common stock

Global Water Resources

Middlesex Water

Pure Cycle

Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares)

Comments

Essential Utilities

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL